Avalo Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Avalo Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2014 to Q3 2024.
  • Avalo Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.9M, a 243% decline year-over-year.
  • Avalo Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$62.9M, a 120% decline year-over-year.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$27.4M, a 26.9% increase from 2022.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$37.4M, a 54.4% increase from 2021.
  • Avalo Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$82.1M, a 12.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$62.9M -$12.9M -$9.11M -243% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$53.8M -$9.58M -$2.43M -33.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$51.3M -$32.8M -$24M -273% Jan 1, 2024 Mar 31, 2024 10-Q/A 2024-07-11
Q4 2023 -$27.4M -$7.66M +$1.2M +13.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-29
Q3 2023 -$28.5M -$3.75M -$7.85M -192% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$20.7M -$7.15M +$4.68M +39.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$25.4M -$8.79M +$12.1M +57.8% Jan 1, 2023 Mar 31, 2023 10-Q/A 2024-07-11
Q4 2022 -$37.4M -$8.85M +$9.11M +50.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-29
Q3 2022 -$46.5M $4.1M +$20.6M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$67.1M -$11.8M +$5.3M +30.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$72.4M -$20.9M +$9.73M +31.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$82.1M -$18M -$1.62M -9.94% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-29
Q3 2021 -$80.5M -$16.5M -$3.19M -24% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$77.3M -$17.1M -$5.31M -45% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$72M -$30.6M +$833K +2.65% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$72.8M -$16.3M -$10.6M -185% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-02
Q3 2020 -$62.2M -$13.3M -$10.4M -364% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$51.8M -$11.8M -$9.27M -364% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-02
Q1 2020 -$42.5M -$31.4M -$26.4M -528% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$16.1M -$5.72M -$4.16M -267% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 -$12M -$2.86M +$21.5M +88.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$33.4M -$2.55M +$3.2M +55.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$36.6M -$5M -$1.25M -33.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$35.4M -$1.56M +$2.8M +64.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$38.2M -$24.3M -$46.2M -211% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $8.06M -$5.75M -$3.98M -224% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 $12M -$3.75M -$1.86M -97.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 $13.9M -$4.36M -$2.67M -158% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 $16.6M $21.9M +$27.9M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-13
Q2 2017 -$11.3M -$1.77M +$1.71M +49.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 -$13M -$1.9M +$3.04M +61.6% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-11
Q4 2016 -$16.1M -$1.69M +$1.99M +54.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$18.1M -$5.96M -$4M -204% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$14.1M -$3.49M -$597K -20.6% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$13.5M -$4.94M -$2.46M -99% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 -$11M -$3.68M Oct 1, 2015 Dec 31, 2015 10-K 2018-04-02
Q3 2015 -$1.96M +$4.04M +67.3% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-08
Q2 2015 -$2.89M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-15
Q1 2015 -$2.48M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-16
Q3 2014 -$6M Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.